Palatin Technologies
Paul Kayne, PhD, has an extensive track record of innovation applied to enable pharmaceutical R&D and life-cycle management. Prior to joining Palatin, Paul held several senior roles at Bristol-Myers Squibb, most recently Head of Discovery Genomics & Proteomics. This trans-national team leveraged big-data biology technologies to drive portfolio progression and regulatory commitments.
Palatin Technologies
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system.